CyDex Pharmaceuticals Initiates Dosing for Phase 2A Oncology Drug Trial.

Business WireMarch 22, 2010

Linked as:

Extract


CyDex Pharmaceuticals Initiates Dosing for Phase 2A Oncology Drug Trial.

Trial to Compare Pharmacokinetics of Captisol-Enabled([R]) Melphalan with Alkeran([R])

LENEXA, Kansas -- CyDex Pharmaceuticals, Inc. today announce...

See the full content of this document

Sponsored links




ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2012, vLex. All Rights Reserved.

Contents in vLex United States

Explore vLex

For Professionals

For Partners

Company